Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1990 Sep;87(18):7100–7104. doi: 10.1073/pnas.87.18.7100

Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75.

L Bokser 1, S Bajusz 1, K Groot 1, A V Schally 1
PMCID: PMC54691  PMID: 2205853

Abstract

Inhibitory effects of the potent antagonist of luteinizing hormone-releasing hormone N-Ac-[3-(2-naphthyl)-D-alanine1,4-chloro-D-phenylalanine2,3- (3-pyridyl)-D- alanine3,D-citrulline6,D-alanine10]luteinizing hormone-releasing hormone (SB-75) free of edematogenic effects were investigated in male rats. In a study to determine the effect on luteinizing hormone levels in castrated male rats, SB-75 was injected s.c. in doses of 0.625, 1.25, 2.5, 5.0, and 10 micrograms. Blood samples were taken at different intervals for 48 hr. All doses of SB-75 significantly decreased luteinizing hormone levels for greater than 6 hr (P less than 0.01); this inhibition lasted for greater than 24 hr (P less than 0.01) with a dose of 5.0 micrograms and greater than 48 hr with 10 micrograms (P less than 0.05). Serum testosterone levels were also measured in intact male rats injected with SB-75 in doses of 25, 50, and 100 micrograms. All doses produced a dramatic fall in testosterone to castration levels 6 hr after injection (P less than 0.01); this inhibition of serum testosterone was maintained for greater than 72 hr, but only the 100-micrograms dose could keep testosterone in the castration range for greater than 24 hr (P less than 0.01). In another study using a specific RIA, we obtained the pharmacokinetic release pattern of SB-75 from two sustained delivery formulations of SB-75 pamoate microgranules and examined their effect on serum testosterone. After a single i.m. injection of 20 mg of one batch of microgranules, a large peak corresponding to SB-75 at 45.8 ng/ml was observed, corresponding to the "burst" effect. Levels of the analog decreased to 19.6 ng/ml on day 2, gradually reached a concentration of 4.7 ng/ml on day 7, and kept declining thereafter. Testosterone levels were reduced on day 1 (P less than 0.01) and were maintained at low values for greater than 7 days (P less than 0.05). In rats injected with 10 mg of SB-75 pamoate microgranules of the second batch, SB-75 serum levels rose to 33 ng/ml 3 hr after administration and then fell gradually to approximately 3.4 ng/ml on day 16, but a second small peak was seen on day 28. Subsequently, the analog levels decreased slowly to 2.9 ng/ml on day 42. At this time, testosterone serum levels were still significantly lower than in controls. These overall results demonstrate the efficacy of SB-75 in the suppression of the pituitary-gonadal axis. This modern luteinizing hormone-releasing hormone antagonist can possibly be used for treating sex hormone-sensitive cancers and other disorders.

Full text

PDF
7104

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajusz S., Csernus V. J., Janaky T., Bokser L., Fekete M., Schally A. V. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res. 1988 Dec;32(6):425–435. doi: 10.1111/j.1399-3011.1988.tb01373.x. [DOI] [PubMed] [Google Scholar]
  2. Bajusz S., Kovacs M., Gazdag M., Bokser L., Karashima T., Csernus V. J., Janaky T., Guoth J., Schally A. V. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1637–1641. doi: 10.1073/pnas.85.5.1637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bokser L., Schally A. V. Delayed release formulation of the somatostatin analog RC-160 inhibits the growth hormone (GH) response to GH-releasing factor-(1-29)NH2 and decreases elevated prolactin levels in rats. Endocrinology. 1988 Oct;123(4):1735–1739. doi: 10.1210/endo-123-4-1735. [DOI] [PubMed] [Google Scholar]
  4. Bokser L., Szende B., Schally A. V. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer. 1990 Jun;61(6):861–865. doi: 10.1038/bjc.1990.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bokser L., Zalatnai A., Schally A. V. Inhibition of pituitary-gonadal axis in mice by long-term administration of D-Trp-6-LHRH microcapsules. J Reprod Fertil. 1989 Mar;85(2):569–574. doi: 10.1530/jrf.0.0850569. [DOI] [PubMed] [Google Scholar]
  6. Csernus V. J., Szende B., Groot K., Redding T. W., Schally A. V. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH. Arzneimittelforschung. 1990 Feb;40(2 Pt 1):111–118. [PubMed] [Google Scholar]
  7. Csernus V. J., Szende B., Schally A. V. Release of peptides from sustained delivery systems (microcapsules and microparticles) in vivo. A histological and immunohistochemical study. Int J Pept Protein Res. 1990 Jun;35(6):557–565. doi: 10.1111/j.1399-3011.1990.tb00262.x. [DOI] [PubMed] [Google Scholar]
  8. Davis M. R., Veldhuis J. D., Rogol A. D., Dufau M. L., Catt K. J. Sustained inhibitory actions of a potent antagonist of gonadotropin-releasing hormone in postmenopausal women. J Clin Endocrinol Metab. 1987 Jun;64(6):1268–1274. doi: 10.1210/jcem-64-6-1268. [DOI] [PubMed] [Google Scholar]
  9. Karten M. J., Rivier J. E. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev. 1986 Feb;7(1):44–66. doi: 10.1210/edrv-7-1-44. [DOI] [PubMed] [Google Scholar]
  10. Leal J. A., Williams R. F., Danforth D. R., Gordon K., Hodgen G. D. Prolonged duration of gonadotropin inhibition by a third generation GnRH antagonist. J Clin Endocrinol Metab. 1988 Dec;67(6):1325–1327. doi: 10.1210/jcem-67-6-1325. [DOI] [PubMed] [Google Scholar]
  11. Mason-Garcia M., Vaccarella M., Horvath J., Redding T. W., Groot K., Orsolini P., Schally A. V. Radioimmunoassay for octapeptide analogs of somatostatin: measurement of serum levels after administration of long-acting microcapsule formulations. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5688–5692. doi: 10.1073/pnas.85.15.5688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mortola J. F., Sathanandan M., Pavlou S., Dahl K. D., Hsueh A. J., Rivier J., Vale W., Yen S. S. Suppression of bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone levels by a potent gonadotropin-releasing hormone antagonist: pharmacodynamic studies. Fertil Steril. 1989 Jun;51(6):957–963. [PubMed] [Google Scholar]
  13. Niswender G. D., Midgley A. R., Jr, Monroe S. E., Reichert L. E., Jr Radioimmunoassay for rat luteinizing hormone with antiovine LH serum and ovine LH-131-I. Proc Soc Exp Biol Med. 1968 Jul;128(3):807–811. doi: 10.3181/00379727-128-33129. [DOI] [PubMed] [Google Scholar]
  14. Redding T. W., Schally A. V. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1983 Mar;80(5):1459–1462. doi: 10.1073/pnas.80.5.1459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Schally A. V., Coy D. H., Arimura A. LH-RH agonists and antagonists. Int J Gynaecol Obstet. 1980;18(5):318–324. doi: 10.1002/j.1879-3479.1980.tb00507.x. [DOI] [PubMed] [Google Scholar]
  16. Schmidt F., Sundaram K., Thau R. B., Bardin C. W. [Ac-D-NAL(2)1,4FD-Phe2,D-Trp3,D-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception. 1984 Mar;29(3):283–289. doi: 10.1016/s0010-7824(84)80008-6. [DOI] [PubMed] [Google Scholar]
  17. Szende B., Redding T. W., Schally A. V. Suppression of meiosis of male germ cells by an antagonist of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1990 Feb;87(3):901–903. doi: 10.1073/pnas.87.3.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Vickery B. H. Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists. Endocr Rev. 1986 Feb;7(1):115–124. doi: 10.1210/edrv-7-1-115. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES